Smith & Nephew 1Q Revenue Rose, Resumes Full-Year Guidance
April 29 2021 - 2:07AM
Dow Jones News
By Matteo Castia
Smith & Nephew PLC on Thursday resumed its full-year
guidance following a revenue increase in the first quarter, thanks
to a return to growth across most divisions.
The medical-technology group said first-quarter revenue rose 12%
year-on-year, or 6.2% on an underlying basis, to $1.26 billion.
Smith & Nephew said reported growth included benefits of
3.4% from foreign-exchange effects and 1.9% from acquisitions.
Meanwhile, all three global franchises of the FTSE 100 company
returned to growth on a reported and underlying basis, it said.
Smith & Nephew said it is now targeting full-year underlying
revenue growth in the range of 10% to 13%, assuming improvement in
conditions through the year.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
April 29, 2021 02:52 ET (06:52 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Mar 2024 to Apr 2024
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Apr 2023 to Apr 2024
